Condition: Relapsed/Refractory Large B-Cell Lymphoma · Sponsor: Shanghai AbelZeta Ltd.
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).
This description comes directly from the study's public registry record.
Weili Zhao, M.D., PhD · 86-021-64370045 · zwl_trial@163.com
Lugui Qiu, M.D., PhD · 86-13821266636 · Qiulg@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Completed |
| Beijing GoBroad Hospital | Beijing, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, China | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, China | Recruiting |
| The First Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, China | Recruiting |
| Jiangxi Cancer Hospital | Nanchang, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, China | Recruiting |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, China | Recruiting |
| Chinese Academy of Medical Sciences Hematology Hospital | Tianjin, China | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05800977